| AbbVie Inc (NYS: ABBV) | | | |
| | | | |
| Exchange rate used is that of the Year End reported date | | | |
| | | | |
| | | | |
| As Reported Annual Cash Flow | | | |
| Report Date | 12/31/2017 | 12/31/2016 | 12/31/2015 |
| Currency | USD | USD | USD |
| Audit Status | Not Qualified | Not Qualified | Not Qualified |
| Consolidated | Yes | Yes | Yes |
| Scale | Thousands | Thousands | Thousands |
| Net earnings | 5309000 | 5953000 | 5144000 |
| Depreciation | 425000 | 425000 | 417000 |
| Amortization of intangible assets | 1076000 | 764000 | 419000 |
| Change in fair value of contingent consideration | 626000 | 228000 | - |
| Stock based compensation | 365000 | 353000 | 282000 |
| Upfront costs & milestones related to collaborations | 470000 | 280000 | 280000 |
| Devaluation loss related to Venezuela | - | 298000 | - |
| Intangible asset impairment | 354000 | - | - |
| Impact related to U.S. tax reform | 1242000 | - | - |
| Other adjustments to reconcile earnings to net cash from operating activities | 84000 | 429000 | 489000 |
| Accounts & other receivables | -391000 | -71000 | -1076000 |
| Inventories | 93000 | -38000 | -434000 |
| Prepaid expenses & other assets | -118000 | -393000 | 511000 |
| Accounts payable & other liabilities | 425000 | -1187000 | 1503000 |
| Net cash flows from operating activities | 9960000 | 7041000 | 7535000 |
| Acquisition of Pharmacyclics, Inc., net of cash acquired | - | -2495000 | -11488000 |
| Other acquisitions & investments | -308000 | -262000 | -964000 |
| Acquisitions of property & equipment | -529000 | -479000 | -532000 |
| Purchases of investment securities | -2230000 | -5315000 | -851000 |
| Sales & maturities of investment securities | 2793000 | 2359000 | 880000 |
| Other investing activities | - | 118000 | 19000 |
| Net cash flows from investing activities | -274000 | -6074000 | -12936000 |
| Net change in short-term borrowings | 22000 | -29000 | -19000 |
| Proceeds from issuance of long-term debt | - | 11627000 | 20660000 |
| Repayments of long-term debt & lease obligations | -25000 | -6010000 | -4018000 |
| Debt issuance cost | - | -69000 | -182000 |
| Dividends paid | -4107000 | -3717000 | -3294000 |
| Purchases of treasury stock | -1410000 | -6033000 | -7567000 |
| Proceeds from the exercise of stock options | 254000 | 268000 | 142000 |
| Payments of contingent consideration liabilities | -268000 | - | - |
| Other financing activities | 22000 | 35000 | 30000 |
| Net cash flows from financing activities | -5512000 | -3928000 | 5752000 |
| Effect of exchange rate changes on cash & equivalents | 29000 | -338000 | -300000 |
| Net increase (decrease) in cash & cash equivalents | 4203000 | -3299000 | 51000 |
| Cash & cash equivalents, beginning of year | 5100000 | 8399000 | 8348000 |
| Cash & cash equivalents, end of year | 9303000 | 5100000 | 8399000 |
| Interest paid, net of portion capitalized | 1099000 | 986000 | 536000 |
| Income taxes paid | 1696000 | 3563000 | 1108000 |
| As Reported Annual Income Statement | | | | | Report Date | 12/31/2017 | 12/31/2016 | 12/31/2015 | | Currency | USD | USD | USD | | Audit Status | Not Qualified | Not Qualified | Not Qualified | | Consolidated | Yes | Yes | Yes | | Scale | Thousands | Thousands | Thousands | | Net revenues | 28216000 | 25638000 | 22859000 | | Cost of products sold | 7040000 | 5833000 | 4500000 | | Selling, general & administrative expense | 6275000 | 5855000 | 6387000 | | Research & development expense | 4982000 | 4366000 | 4285000 | | Acquired in-process research & development expense | 327000 | 200000 | 150000 | | Total operating costs & expenses | 18624000 | 16254000 | 15322000 | | Operating earnings | 9592000 | 9384000 | 7537000 | | Interest expense | 1150000 | 1047000 | 719000 | | Interest & dividend income | 146000 | 82000 | 33000 | | Interest income (expense), net | -1004000 | -965000 | -686000 | | Net foreign exchange gain (loss) | -348000 | -303000 | -193000 | | Other income (expense), net | -513000 | -232000 | -13000 | | Earnings before income tax - domestic | -2678000 | -1651000 | -1038000 | | Earnings before income tax - foreign | 10405000 | 9535000 | 7683000 | | Earnings before income tax expense | 7727000 | 7884000 | 6645000 | | Current domestic income tax expense | 6204000 | 2229000 | 1036000 | | Current foreign income tax expense | 376000 | 498000 | 313000 | | Current income tax expense | 6580000 | 2727000 | 1349000 | | Deferred domestic income tax expense (benefit) | -4898000 | -792000 | 141000 | | Deferred foreign income tax expense (benefit) | 736000 | -4000 | 11000 | | Deferred income tax expense (benefit) | -4162000 | -796000 | 152000 | | Income tax expense | 2418000 | 1931000 | 1501000 | | Net earnings | 5309000 | 5953000 | 5144000 | | Earnings allocated to participating securities | 26000 | 30000 | 26000 | | Net income available to common shareholders | 5283000 | 5923000 | 5118000 | | Weighted average shares outstanding - basic | 1596000 | 1622000 | 1625000 | | Weighted average shares outstanding - diluted | 1603000 | 1631000 | 1637000 | | Year end shares outstanding | 1592131.025 | 1592512.72 | 1609892.94 | | Earnings per share - basic | 3.31 | 3.65 | 3.15 | | Earnings per share - diluted | 3.3 | 3.63 | 3.13 | | Cash dividends declared per common share | 2.63 | 2.35 | 2.1 | | Total number of employees | 29000 | 30000 | 28000 | | Number of common stockholders | 50095 | 52270 | 53653 | | Foreign currency translation adjustments | - | -165000 | -667000 | | As Reported Annual Balance Sheet | | | | | Report Date | 12/31/2017 | 12/31/2016 | 12/31/2015 | | Currency | USD | USD | USD | | Audit Status | Not Qualified | Not Qualified | Not Qualified | | Consolidated | Yes | Yes | Yes | | Scale | Thousands | Thousands | Thousands | | Cash & cash equivalents | 9303000 | 5100000 | 8399000 | | Short-term investments | 486000 | 1323000 | 8000 | | Accounts receivable, gross | 5146000 | 4830000 | 4808000 | | Less: allowance - accounts receivable | 58000 | 72000 | 78000 | | Accounts receivables, net | 5088000 | 4758000 | 4730000 | | Finished goods | 610000 | 223000 | 469000 | | Work in process | 822000 | 1080000 | 1081000 | | Materials | 173000 | 141000 | 169000 | | Inventories | 1605000 | 1444000 | 1719000 | | Prepaid expenses & other current assets | 4741000 | 3562000 | 1458000 | | Total current assets | 21223000 | 16187000 | 16314000 | | Investments | 2090000 | 1783000 | 145000 | | Land | 48000 | 46000 | 46000 | | Buildings | 1428000 | 1344000 | 1284000 | | Equipment | 5991000 | 5726000 | 5656000 | | Construction in progress | 604000 | 410000 | 348000 | | Property & equipment, gross | 8071000 | 7526000 | 7334000 | | Less: accumulated depreciation | 5268000 | 4922000 | 4769000 | | Property & equipment, net | 2803000 | 2604000 | 2565000 | | Intangible assets, net of amortization | 27559000 | 28897000 | 19709000 | | Goodwill | 15785000 | 15416000 | 13168000 | | Other assets | 1326000 | 1212000 | 1149000 | | Total assets | 70786000 | 66099000 | 53050000 | | Short-term borrowings | 400000 | 377000 | 406000 | | Current maturities of long-term debt & lease obligations | 6015000 | 25000 | 2025000 | | Sales rebates | 3069000 | 2887000 | 2355000 | | Accounts payable | 1474000 | 1407000 | 1597000 | | Dividends payable | 1143000 | 1028000 | 924000 | | Salaries, wages & commissions | 763000 | 644000 | 632000 | | Royalty & license arrangements | 514000 | 434000 | 411000 | | Other accounts payable & accrued liabilities | 3263000 | 2979000 | 2544000 | | Accounts payable & accrued liabilities | 10226000 | 9379000 | 8463000 | | Total current liabilities | 16641000 | 9781000 | 10894000 | | Notes | 35502000 | 34964000 | 27400000 | | Term loan facilities | 2000000 | 2000000 | 4000000 | | Other long-term debt & lease obligations | 110000 | 113000 | 139000 | | Fair value hedges & unamortized bond discounts | - | -338000 | -72000 | | Fair value hedges | -401000 | - | - | | Unamortized bond discounts | -97000 | -110000 | -85000 | | Unamortized deferred financing costs | -146000 | -164000 | -117000 | | Total long-term debt & lease obligations | 36968000 | 36465000 | 31265000 | | Current portion | 6015000 | 25000 | 2025000 | | Long-term debt & lease obligations | 30953000 | 36440000 | 29240000 | | Deferred income taxes | 2490000 | 6890000 | 5276000 | | Other long-term liabilities | - | 3941000 | - | | Contingent consideration liabilities | 4266000 | - | - | | Pension & other post-employment benefits | 2740000 | 2085000 | 1949000 | | Liabilities for unrecognized tax benefits | 2683000 | 1166000 | 902000 | | Income taxes payable | 4675000 | - | - | | Other long-term liabilities | 1241000 | 1160000 | 844000 | | Other long-term liabilities | 15605000 | 8352000 | 3695000 | | Common stock | 18000 | 18000 | 17000 | | Common stock held in treasury | 11923000 | 10852000 | 8839000 | | Additional paid-in capital | 14270000 | 13678000 | 13080000 | | Retained earnings | 5459000 | 4378000 | 2248000 | | Foreign currency translation adjustments | -439000 | -1435000 | -1270000 | | Net investment hedging | -203000 | 140000 | - | | Pension & other post-employment benefits | -1919000 | -1513000 | -1378000 | | Unrealized gains on marketable equity securities | - | 46000 | 47000 | | Hedging activities | -166000 | 176000 | 40000 | | Accumulated other comprehensive income (loss) | -2727000 | -2586000 | -2561000 | | Total stockholders' equity | 5097000 | 4636000 | 3945000 | | | | | | | | |